Zagreb regimen, an abbreviated intramuscular schedule for rabies vaccination

Clinical and Vaccine Immunology

Volumn 22, Issue 1, 2015, Pages 1-5

  Ren, Jiangping ^a   Yao, Linong ^a   Sun, Jimin ^a   Gong, Zhenyu ^a  

^a ZHEJIANG PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DIPLOID CELL VACCINE; FETAL BOVINE KIDNEY CELL VACCINE; PRIMARY CHICKEN EMBRYO CELL VACCINE; PURIFIED DUCK EMBRYO VACCINE; PURIFIED VERO CELL RABIES VACCINE; RABIES IMMUNOGLOBULIN; RABIES VACCINE; SUCKLING MOUSE BRAIN VACCINE; UNCLASSIFIED DRUG;

AFRICA; ANTIBODY RESPONSE; ASIA; DRUG SAFETY; HEALTH CARE COST; HUMAN; IMMUNOGENICITY; INCIDENCE; INTRAMUSCULAR DRUG ADMINISTRATION; MORTALITY; NONHUMAN; PATIENT COMPLIANCE; POST EXPOSURE PROPHYLAXIS; RABIES; RABIES VIRUS; REVIEW; SEROCONVERSION; UNSPECIFIED SIDE EFFECT; VACCINATION; CROATIA; ECONOMICS; IMMUNIZATION; IMMUNOLOGY; MEDICATION COMPLIANCE; PROCEDURES;

CROATIA; HUMANS; IMMUNIZATION SCHEDULE; INJECTIONS, INTRAMUSCULAR; MEDICATION ADHERENCE; POST-EXPOSURE PROPHYLAXIS; RABIES; RABIES VACCINES; VACCINATION;

EID: 84920507355     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00531-14     Document Type: Review

References (35)

1. World Health Organization. 2013. Rabies. Accessed 18 November 2013. http://www.who.int/mediacentre/factsheets/fs099/en/.
2. World Health Organization. 2010. Rabies vaccines: WHO position paper-recommendations. Vaccine 28: 7140-7142. http://dx.doi.org/10.1016/j.vaccine.2010.08.082.
3. Yin C, Zhou H, Wu H, Tao X, Rayner S, Wang S, Tang Q, Liang G. 2012. Analysis on factors related to rabies epidemic in China from 2007-2011. Virol Sin 27: 132-143. http://dx.doi.org/10.1007/s12250-012-3244-y.
4. Knobel DL, Cleaveland S, Coleman PG, Fevre EM, Meltzer MI, Miranda ME, Shaw A, Zinsstag J, Meslin F. 2005. Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ 83: 360-368.
5. WHO. 2010. Rabies vaccines: WHO position paper. Wkly Epidemiol Rec 85: 309-320. http://www.who.int/wer/2010/wer8532/en/.
6. Sudarshan MK, Madhusudana SN, Mahendra BJ, Rao NS, Ashwath Narayana DH, Abdul Rahman S, Meslin FX, Lobo D, Ravikumar K, Gangaboraiah. 2007. Assessing the burden of human rabies in India: results of a national multi-center epidemiological survey. Int J Infect Dis 11: 29-35. http://dx.doi.org/10.1016/j.ijid.2005.10.007.
7. Chinese Center for Disease Control and Prevention. 2013. The national statistical for the incidence and mortality of notifiable infectious disease. Accessed 18 November 2013. (In Chinese.) http://chinacdc.cn/AnalysisService/showFlashKY.jsp?id-010213941550107970001636100000&name-2012.doc.
8. National Health and Family Planning Commission of the People's Republic of China. 2013. Chinese Yearbook of Health Statistics 2012. Accessed 18 November 2013. (In Chinese.) http://www.nhfpc.gov.cn/htmlfiles/zwgkzt/ptjnj/year2012/index2012.html.
9. Song M, Tang Q, Wang D, Mo Z, Guo S, Li H, Tao X, Rupprecht CE, Feng Z, Liang G. 2009. Epidemiological investigations of human rabies in China. BMC Infect Dis 9: 210. http://dx.doi.org/10.1186/1471-2334-9-210.
10. Hu R, Tang Q, Tang J, Fooks AR. 2009. Rabies in China: an update. Vector Borne Zoonotic Dis 9: 1-12. http://dx.doi.org/10.1089/vbz.2008.0046.
11. Yu JN, Li H, Tang Q, Tao XY, Wu H, Mo ZJ, Zhang H, Wang D, Weng J, Shen R, Zhu F, Wang X, Liu H, Shen X, Wang S. 2010. Study on the status of infection and distribution of rabies virus in China. Zhonghua Liu Xing Bing Xue Za Zhi 31: 521-524. (In Chinese.) http://d.wanfangdata.com.cn/Periodical-zhlxbx201005011.aspx.
12. Gong Z, He F, Chen Z. 2012. Risk factors for human rabies in China. Zoonoses Public Health 59: 39-43. http://dx.doi.org/10.1111/j.1863-2378.2011.01416.x.
13. Zhang Y, Xiong C, Xiao D, Jiang R, Wang Z, Zhang LZ. 2005. Human rabies in China. Emerg Infect Dis 11: 1983-1984. http://dx.doi.org/10 .3201/eid1112.040775.
14. Fescharek R, Franke V, Samuel MR. 1994. Do anaesthetics and surgical stress increase the risk of post-exposure rabies treatment failure? Vaccine 12: 12-13. http://dx.doi.org/10.1016/0264-410X(94)90004-3.
15. Vodopija I, Sureau P, Smerdel S, Lafon M, Baklaic Z, Ljubicic M, Svjetlicic M. 1988. Interaction of rabies vaccine with human rabies immunoglobulin and reliability of a 2-1-1 schedule application for postexposure treatment. Vaccine 6: 283-286. http://dx.doi.org/10.1016/0264-410X(88)90225-3.
16. Vodopija I, Sureau P, Lafon M, Baklaic Z, Ljubicic M, Svjetlicic M, Smerdel S. 1986. An evaluation of second generation tissue culture rabies vaccines for use in man: a four-vaccine comparative immunogenicity study using a pre-exposure vaccination schedule and an abbreviated 2-1-1 postexposure schedule. Vaccine 4: 245-248.
17. Zanetti CR, Lee LM, Chaves LB, Rodrigues JL, Eleuterio GC, Pereira OA. 1995. Studies on human anti-rabies immunization in Brazil. II. Preliminary evaluation of the 2-1-1 schedule for human pre-exposure antirabies immunization, employing suckling mouse brain vaccine. Rev Inst Med Trop Sao Paulo 37: 353-356.
18. Lv ZH, Cao YX, Gao HQ. 2011. Study on efficacy and safety of rabies vaccine by three different immunization programs. J Shanxi Med Univ 42: 742-744. (In Chinese.) http://dx.doi.org/10.3969/J.ISSN.1007-6611.2011.09.012.
19. Liu XB. 2011. The comparative observation of wild dog vaccine immune program and five needle 2-1-1 four needles of immunization programs. Chin J Mod Drug Appl 5: 2-3. (In Chinese.) http://www.cqvip.com/QK/88776X/201122/40427733.html.
20. Liu H, Huang G, Tang Q, Li J, Cao S, Fu C, Cao Q, Liu B, Pan H, Wang M. 2011. The immunogenicity and safety of vaccination with purified Vero cell rabies vaccine (PVRV) in China under a 2-1-1 regimen. Hum Vaccin 7: 220-224. http://dx.doi.org/10.4161/hv.7.2.14003.
21. Li JH, Ye F, Chai LM. 2012. Observation on the safety and immunogenicity of antirabic vaccine among different immune procedures. J Med Pest Control 28: 667-669. (In Chinese.) http://mall.cnki.net/magazine/Article/YXDZ201206027.htm.
22. Hu Q, Liu MQ, Zhu ZG, Zhu ZR, Lu S. 2014. Comparison of safety and immunogenicity of purified chick embryo cell vaccine using Zagreb and Essen regimens in patients with category II exposure in China. Hum Vaccin Immunother 10: 1645-1649. http://dx.doi.org/10.4161/hv.28420.
23. Chutivongse S, Wilde H, Fishbein DB, Baer GM, Hemachudha T. 1991. One-year study of the 2-1-1 intramuscular postexposure rabies vaccine regimen in 100 severely exposed Thai patients using rabies immune globulin and Vero cell rabies vaccine. Vaccine 9: 573-576.
24. Vodopija R, Lafont M, Baklaic Z, Ljubicic M, Svjetlicic M, Vodopija I. 1997. Persistence of humoral immunity to rabies 1100 days after immunization and effect of a single booster dose of rabies vaccine. Vaccine 15: 571-574. http://dx.doi.org/10.1016/S0264-410X(97)00207-7.
25. Lang J, Simanjuntak GH, Soerjosembodo S, Koesharyono C. 1998. Suppressant effect of human or equine rabies immunoglobulins on the immunogenicity of post-exposure rabies vaccination under the 2-1-1 regimen: a field trial in Indonesia. MAS054 Clinical Investigator Group. J Bull World Health Organ 76: 491-495.
26. Vodopija I, Baklaic Z, Vodopija R. 1999. Rabipur: a reliable vaccine for rabies protection. Vaccine 17: 1739-1741. http://dx.doi.org/10.1016/S0264-410X(98)00427-7.
27. Wang GH, Zhang JH, Qi GH. 2013. The comparative observation of adverse reactions between "2-1-1" and traditional "5-doses" regimen. Chin J Biol 26: 400-401. (In Chinese.) http://www.cnki.com.cn/Article/CJFDTotal-SWZP201303025.htm.
28. Huang SX, Zhang ZK, Feng HB, Pan M, Ren ZH. 2013. Analysis on adverse reaction rate of rabies vaccine and its influencing factors. Chin J Biol 26: 1154-1157. (In Chinese.) http://www.cnki.com.cn/Article/CJFDTOTAL-SWZP201308025.htm.
29. Zhang HY, Chen JH, Weng DL. 2013. Observation of the side effects induced by rabies vaccine of "2-1-1" procedure. Med Infect 5: 190-191. (In Chinese.) http://www.cqvip.com/QK/98226B/201305/45028298.html.
30. Xie FX, Qiu T. 2012. Comparative study on the safety of rabies vaccine for human use under four immune procedures between ChengDa and Rabipur. J Dis Monit Control 6: 456-458. (In Chinese.) http://d.wanfangdata.com.cn/Periodical-jbjcykz201208004.aspx.
31. Goswami A, Plun-Favreau J, Nicoloyannis N, Sampath G, Siddiqui MN, Zinsou JA. 2005. The real cost of rabies post-exposure treatments. Vaccine 23: 2970-2976. http://dx.doi.org/10.1016/j.vaccine.2004.12.008.
32. Wang CL, Zhang XW, Yu YX. 2010. Study on the compliance and economic cost of rabies vaccination. Chin J Vaccine Immun 16: 254-257. (In Chinese.) http://www.cnki.com.cn/Article/CJFDTotal-ZGJM201003022.htm.
33. Yang JY, Lin LX, Zhou XM, Xu LW. 2012. Economic burden and compliance analysis of human rabies vaccine in Meizhou. South China J Prev Med 38: 44-46. (In Chinese.) http://www.cnki.com.cn/Article/CJFDTotal-GDWF201203013.htm.
34. Chen RN, Lin WG, Chen PZ, Zeng QS. 2011. Analysis of compliance for rabies vaccination. J Trop Med 11: 1076-1077. (In Chinese.) http://www.cnki.com.cn/Article/CJFDTotal-RDYZ201109031.htm.
35. Yang B. 2012. Discussion on the "2-1-1" procedure for rabies vaccine. Chin J Public Health Manag 28: 471-472. (In Chinese.) http://www.cnki.com.cn/Article/CJFDTotal-GGWS201204052.htm.